Chemotherapy News and Research

Latest Chemotherapy News and Research

Genetic variation associated with MUC5B gene may increase risk of developing Pulmonary Fibrosis

Genetic variation associated with MUC5B gene may increase risk of developing Pulmonary Fibrosis

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

Cancer Centers of North Carolina buys WROS from Wake Radiology

Cancer Centers of North Carolina buys WROS from Wake Radiology

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Minimizing neurological side effects in high-grade glioma patients may improve survival

Minimizing neurological side effects in high-grade glioma patients may improve survival

New findings show relation between breast implants and anaplastic large cell lymphoma

New findings show relation between breast implants and anaplastic large cell lymphoma

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

Researchers deploy new tool in study of tubulin tyrosine ligase in tumor growth

Researchers deploy new tool in study of tubulin tyrosine ligase in tumor growth

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Mount Sinai's new Dubin Breast Center to provide patients with seamless care

Mount Sinai's new Dubin Breast Center to provide patients with seamless care

Seattle enters second ADC research collaboration agreement with Genmab

Seattle enters second ADC research collaboration agreement with Genmab

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

Bedford Labs launches cancer drug Topotecan Hydrochloride for Injection

Bedford Labs launches cancer drug Topotecan Hydrochloride for Injection

Biotech Synergy concludes EP-2101 asset transfer, cancer epitopes related portfolio

Biotech Synergy concludes EP-2101 asset transfer, cancer epitopes related portfolio

Novocure's NovoTTF-100A System receives FDA approval for GBM treatment

Novocure's NovoTTF-100A System receives FDA approval for GBM treatment

NVP-BEZ235 inhibits growth of ovarian cancer cells, increases survival: Study

NVP-BEZ235 inhibits growth of ovarian cancer cells, increases survival: Study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.